[Octreotide + bilateral adrenalectomy in the management of ACTH-producing carcinoid tumors]

Arq Bras Endocrinol Metabol. 2005 Oct;49(5):791-6. doi: 10.1590/s0004-27302005000500020. Epub 2006 Jan 23.
[Article in Portuguese]

Abstract

Cushing's syndrome (CS) due to ectopic ACTH secretion has a high morbidity and mortality. Thus, rapid treatment of ectopic CS is mandatory. Carcinoid tumors associated with ectopic ACTH (CTu-ACTH) syndrome represent a more severe clinical picture, due to the carcinoid symptoms that worsen the hypercortisolism state. Management of patients with CTu-ACTH should include the control of hypercortisolism, as well as the carcinoid disturbance. We report 3 patients (2F, 1M) with CTu-ACTH (2 pancreatic, 1 occult) who presented with clinical manifestations of CS (n= 3) and carcinoid syndrome (2): 2 were initially investigated for CS and 1 carcinoid syndrome. In all hypokalemia, hypertension and diabetes mellitus were associated with severe hypercortisolism and high ACTH levels. Administration of octreotide-LAR reduced ACTH levels from 230,000 to 30,000 pg/ml in patient 1, and controlled symptoms of carcinoid syndrome and neoplasic lesions in patient 2; treatment with subcutaneous octreotide in patient 3 controlled carcinoid syndrome and partially reduced symptoms of hypercortisolism. All 3 patients were submitted to bilateral adrenalectomy to control CS. Our data show that combined anti-neoplastic therapy may contribute to the stabilization and/or definitive control of CTu-ACTH.

Publication types

  • Case Reports

MeSH terms

  • Adrenalectomy / methods
  • Adrenocorticotropic Hormone / metabolism*
  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Carcinoid Tumor / metabolism
  • Carcinoid Tumor / therapy*
  • Combined Modality Therapy / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Proteins / metabolism*
  • Octreotide / therapeutic use*
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Neoplasm Proteins
  • Adrenocorticotropic Hormone
  • Octreotide